Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, Quebec, H3T 1J4, Canada.
Department of Medicine, Université de Montréal, Montreal, Quebec, H3T 1J4, Canada.
Genome Med. 2019 Apr 30;11(1):29. doi: 10.1186/s13073-019-0642-x.
The nature of the tumor antigens that are detectable by T cells remains unclear. In melanoma, T cells were shown to react against major histocompatibility complex (MHC)-associated peptides (MAPs) that are derived from exonic mutations. A recent multi-omic study of hepatocellular carcinomas suggests, however, that mutated exonic MAPs were exceedingly rare, bringing the accuracy of the current methods for antigen identification into question and demonstrating the importance of broadening tumor-antigen discovery efforts.
肿瘤抗原中哪些能被 T 细胞识别，其性质尚不清楚。在黑色素瘤中，T 细胞被证明能对抗主要组织相容性复合体（MHC）相关肽（MAP），这些 MAP 来源于外显子突变。然而，最近对肝细胞癌的多组学研究表明，突变的外显子 MAP 极为罕见，这使得当前抗原识别方法的准确性受到质疑，并证明了扩大肿瘤抗原发现工作的重要性。
